Sign inJoin waitlistJoin the waitlist

NB

Nusayba Bagegni

Physician · Washington University School of Medicine

Credentials: · · · · ·

History

Washington University School of Medicine
Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2013–2016
Internal Medicine
Barnes-Jewish Hospital
2010–2013
University of Iowa Roy J. and Lucille A. Carver College of Medicine
2006–2010
University of Missouri, Columbia, MO

Research

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
Nature Communications · 2018 · 169 citations
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
Breast Cancer Research · 2017 · First of 17 authors · 63 citations
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
PLoS ONE · 2019 · First of 3 authors · 40 citations

Foluso Ademuyiwa
8 papers
CM
Cynthia Ma
7 papers
Katherine Clifton
7 papers
LP
Lindsay Peterson
5 papers
Mateusz Opyrchal
5 papers
RB
Ron Bose
5 papers
Ashley Frith
4 papers
Katherine Weilbaecher
4 papers
RS
Rama Suresh
4 papers
Aditya Bardia
3 papers
CR
Caron Rigden
3 papers
Imran Zoberi
3 papers

Clinical trials

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Washington University School of Medicine
2024–2027
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Principal investigator · Recruiting
Washington University School of Medicine
2022–2030
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2021–2027
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Principal investigator · Terminated · Phase 1
Washington University School of Medicine
2018–2020